For patients aged 6 years and older with POMC deficiency, PCSK1 deficiency, LEPR deficiency, or BBS, MC4R agonists are approved which could be considered when available and reimbursed. The gene discussed is MC4R; the disease is obesity due to pro-opiomelanocortin deficiency.